Future progress will depend on identifying biomarkers that define NF-κB driven obesity phenotypes, refining tissue-targeted delivery platforms, and conducting longer, more carefully stratified clinical trials. This evidence concerns the gene NFKB1 and obesity due to melanocortin 4 receptor deficiency.